Colin C Pritchard
Overview
Explore the profile of Colin C Pritchard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
13238
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adil M, Kolarova T, Doebley A, Chen L, Tobey C, Galipeau P, et al.
Nat Med
. 2025 Feb;
PMID: 39939524
Preeclampsia is characterized by placental dysfunction and results in significant morbidity, but reliable early prediction remains challenging. We investigated whether clinically obtained prenatal cell-free DNA (cfDNA) screening (PDNAS) using whole-genome...
2.
Raychaudhuri R, Tuchayi A, Low S, Arafa A, Graham L, Gulati R, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39920014
Background And Objective: The prostate-specific membrane antigen (PSMA) radioligand Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC...
3.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
4.
Cheng H, Shevach J, Castro E, Couch F, Domchek S, Eeles R, et al.
JAMA Oncol
. 2024 Jul;
10(9):1272-1281.
PMID: 39052257
Importance: Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in...
5.
Giustini N, Pritchard C, Kamat N, Menon M
JCO Precis Oncol
. 2024 Jul;
8:e2300215.
PMID: 38991179
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.
6.
Raychaudhuri R, DeJong M, Rettig M, Yu E, Gulati R, Schweizer M, et al.
Eur Urol
. 2024 Jun;
87(3):375-376.
PMID: 38890069
No abstract available.
7.
Cranmer L, Konnick E, Yoshida J, Jacobson A, Malik B, Mogal H, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2300455.
PMID: 38885448
Highlighting here a patient case with neuroblastoma, renal cancer & GIST from germline SDHA.
8.
Raychaudhuri R, Mo G, Tuchayi A, Graham L, Gulati R, Pritchard C, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300634.
PMID: 38662984
Purpose: While Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer...
9.
Viscuse P, Slack-Tidwell R, Zhang M, Rohra P, Zhu K, San Lucas F, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136389
(AVPCs) are a subset of metastatic castrate-resistant prostate cancers (mCRPCs) characterized by defects in ≥ two of three of , , and (AVPCm), a profile linked to lineage plasticity, androgen...
10.
Kwon R, Cheng H, Pritchard C
JAMA Oncol
. 2023 Oct;
9(12):1725-1726.
PMID: 37883072
No abstract available.